Alzheimer's Index
5335 views
Rate Now: 1 2 3 4

average rating: 3.50 / 2 ratings
Created by Barrons
DESCRIPTION:

Date updated:03-31-2007

"When Alzheimer's drugs arrive, they will do much good for the estimated 440,000 Americans that develop the disease each year. More than 5 million suffer from Alzheimer's in the U.S., according to the latest estimates from the Alzheimer's Association, and perhaps 24 million suffer worldwide."

The following are a few companies that develop drugs for Alzheimer's patients.

From Barron's 4/2/07

symbol name last price % change open
  • +
  • WYE
    Wye
  • $0.00
  • N/A
  • $N/A

From Barron's 4/2/07 "Essner's company (ticker: WYE) has made a broad investment in Alzheimer's research, bringing 11 drugs into clinical human testing. Its lead compound is a genetically engineered antibody developed with the Irish firm Elan (ADR ticker: ELN) that actually clears away the toxic protein that clots Alzheimer's patients' brains. Other Wyeth compounds inhibit the formation of those Alzheimer's clumps."

People owning WYE also tend to own: ARXTCALPCAMH.OBFXIGSTLJTXKMP

TheStreet.com Rating: B What is this?

  • +
  • NRMX
    N/a
  • $2.00
  • 0.00
  • $2.00

From Barron's 4/2/07 "The farthest along of the anti-amyloid experimental drugs are Myriad's Flurizan and Neurochem's Alzhemed, both of which are in the Phase 3 trials that come just prior to seeking FDA approval...The future of Canada's Neurochem basically rides on Alzhemed, an experimental drug that's like an anti-coagulant that binds to single copies of A-beta42 and reduces their tendency to clump together."

People owning NRMX also tend to own: AMKRANADBDYCBAKENZFRGIOC

TheStreet.com Rating: No Rating What is this?

  • +
  • ELN
    Elan Cp Plc Adr
  • $6.58
  • +6.13%
  • $6.11

From Barron's 4/2/07 "Essner's company (ticker: WYE) has made a broad investment in Alzheimer's research, bringing 11 drugs into clinical human testing. Its lead compound is a genetically engineered antibody developed with the Irish firm Elan (ADR ticker: ELN) that actually clears away the toxic protein that clots Alzheimer's patients' brains. Other Wyeth compounds inhibit the formation of those Alzheimer's clumps."

People owning ELN also tend to own: AMGNBWNGIASGITKG.OBBBYHOFFMOT

TheStreet.com Rating: No Rating What is this?

  • +
  • NVS
    Novartis Ag Ads
  • $52.80
  • +0.42%
  • $52.33

From Barron's 4/2/07 "Pfizer's Aricept and Novartis' Exelon prevent the breakdown of the neurotransmitter acetylcholine that's part of the mechanism of memory (as does Cognex, which Pfizer no longer actively markets)."

People owning NVS also tend to own: ANNAUYBACBHIERICFGE

TheStreet.com Rating: B What is this?

  • +
  • PFE
    Pfizer Inc
  • $16.96
  • -0.35%
  • $17.01

From Barron's 4/2/07 "Pfizer's Aricept and Novartis' Exelon prevent the breakdown of the neurotransmitter acetylcholine that's part of the mechanism of memory (as does Cognex, which Pfizer no longer actively markets)."

People owning PFE also tend to own: AAALLAPCBUDCOPCVXDOW

TheStreet.com Rating: C+ What is this?

  • +
  • LLY
    Lilly Eli Co
  • $34.50
  • +0.20%
  • $34.39

From Barron's 4/2/07 Produces a drug which "inhibits gamma secretase enzyme from making amyloid beta"

People owning LLY also tend to own: CCLXCVSGOOGGSHDJNJ

TheStreet.com Rating: C What is this?

  • +
  • MYGN
    Myriad Genetics
  • $24.38
  • 0.00%
  • $N/A

From Barron's 4/2/07 "The farthest along of the anti-amyloid experimental drugs are Myriad's Flurizan and Neurochem's Alzhemed, both of which are in the Phase 3 trials that come just prior to seeking FDA approval."

People owning MYGN also tend to own: MIKRSWFTCPHDCRDCINFYNKTRSAY

TheStreet.com Rating: B- What is this?

  • +
  • JNJ
    Johnson And Johns
  • $60.30
  • +0.53%
  • $59.94

From Barron's 4/2/07 Produces a drug which "inhibits breakdown of memory neurotransmitters"

People owning JNJ also tend to own: AAAIGIBMINTCJPMKOMSFT

TheStreet.com Rating: B What is this?

  • Page 1 of 2
  • 1
  • 2
previous next

Portfolio not tracked!

Comments not available

ADD YOUR COMMENTS:

latest articles | popular forums
Jim Cramer's Portfolios of the Week

By Roberto Pedone Posted on Nov. 6, 2009 According to Jim Cramer, the bears are tellinginvestors six lies. On Wednesday’s “Mad Money” TV show, Cramer said if you ...

11.06.09 | 15:52 PM
'Fast Money' Portfolios of the Week

By Roberto Pedone Posted on Nov. 5, 2009 The traders on CNBC’s “Fast Money” told their viewers what they must know after Warren Buffett announced on Tuesday his l...

11.05.09 | 12:05 PM
Squeezing the Shorts: Late Earni...

By Jonas Elmerraji Posted on Nov. 4, 2009 For investors who seek out short-squeeze opportunities, there’s no time as important as earnings season. Earnings are one of...

11.04.09 | 15:18 PM
Cramer's Take on Headline Stocks...

By Stockpickr Staff Posted on Nov. 4, 2009 Regardless of why a stock is in the news, it never hurts to hear what a professional investor has to say about it. The key is...

11.04.09 | 11:12 AM
more articles
General market Technical Analysi...
11.14.07 | 22:55 PM From author ZA
Banjo's Garden Pic Thread
05.10.09 | 12:33 PM From author banjoman
The Presidential/Political Thread
01.02.08 | 08:05 AM From author Dave Cox
BIOTECH
07.26.09 | 11:32 AM From author CallaLilly
more forums
recent answers | popular answers
bubble(0)
today 's lists
Biggest % Gainers

Here are some of the largest % gainers from Nov. 2, 2009. more

Biggest % Losers

Here is the stock list of some of the largest % losers from Nov. 2, 2009. more

52-Week Highs

Here are some of the biggest stocks that made the 52-week high list on Nov. 2, 2009. more

show all today's lists